[Previous Months][Date Index][Thread Index][Join - Register][Login]   Help@Insulin-Pumpers.org
  [Message Prev][Message Next][Thread Prev][Thread Next]   for subscribe/unsubscribe assistance

[IP] FDA warning on Disetronic insulin pump plant

Roche gets FDA warning on insulin pump plant

NEW YORK, July 15 (Reuters) - U.S. regulators have issued a warning letter to 
 Roche Diagnostics Corp. regarding what they said were "serious problems" in the
manufacturing of insulin pumps at one of its plants in Switzerland.

In a letter dated June 11, but posted on the FDA Web site on Tuesday, the U.S. 
Food and Drug Administration said it uncovered a variety of violations during 
inspections of the Disetronic Medical Systems plant in Burgdorf, Switzerland 
from Jan. 27 to Feb. 5.

 Disetronic, which was acquired by Swiss health care company Roche Holding AG in
early May, responded to the issues raised by the inspection on three separate 

 But the FDA, in its warning letter, called the responses dated March 5, April 3
 and May 6 "inadequate" and said they failed to provide proper documentation the
problems had been corrected.

The FDA said the methods or controls used in the manufacture, packing, storage 
or installation of the devices did not conform with its requirements.

 The FDA letter said the violations found in the inspection, "may be symptomatic
of serious underlying problems in the Disetronic manufacturing and quality 
assurance systems" and warned that all Disetronic Medical Systems products may 
be detained on entry into the United States "until these violations are 

Roche Diagnostics spokesman Joel Reuter said the company was doing everything 
it could to bring all Disetronic facilities up to standards. He pointed out 
that the violations were uncovered prior to Roche's acquisition of Disetronic.

"We have been working very hard over the last several weeks to resolve these 
issues," said Reuter, adding that the company was working closely with the FDA 
to make sure all of the agency's concerns are addressed.

Roche Diagnostics is a division of Roche Holding AG.

The U.S. regulators said they would likely need to conduct a follow-up 
inspection to verify that the company had corrected the problems.
for HELP or to subscribe/unsubscribe, contact: